The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | MRD-negativity as a surrogate for PFS and OS
Philippe Moreau, MD, Nantes University Hospital, Nantes, France, discusses the use of measurable residual disease (MRD) negativity as a surrogate for progression-free survival (PFS) and overall survival (OS) in both the frontline and relapsed/refractory setting. Prof. Moreau explores the key questions regarding the use of MRD, such as what the optimal techniques are to obtain the measure, such as through flow cytometry or next-generation sequencing (NGS), as well as what the optimal MRD threshold is. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
